Several years ago, one of us decided to donate a kidney to someone who needed one. She didn’t anticipate the difficulties that would arise from the process by which donors are evaluated.

Aducanumab has just been approved by the Food and Drug Administration to slow the progress of Alzheimer’s disease. It is likely that many people who are candidates for the drug will no longer be competent to make their own health care decisions, and will be relying heavily on others to make the decision with them or for them. As a layperson, how would I evaluate the risks and benefits of this drug, were I acting as a health care proxy for someone with Alzheimer’s disease?

June 7, 2021, was a bad day for science. That was the day Food and Drug Administration approved aducanumab for the treatment of Alzheimer’s disease, even though a committee of its own selected experts recommended strongly against approval.

In late May, an international organization eliminated a 40-year prohibition against human embryo research beyond 14 days. The legal and scientific consequences will vary around the world.

The American myth of rugged individualism, which often means “pulling yourself up by your own bootstraps,” is outdated, was never completely accurate. It is on full display during the coronavirus pandemic, contributing to cases and deaths.

The United States, Russia, and China support temporary patent waivers for Covid vaccines. The waivers, which need support from other countries, would likely save lives in low- and middle-income countries.

Changes in abortion law threaten to undermine a major benefit of prenatal diagnosis, namely the ability of pregnant women to choose whether or not to continue their pregnancies upon learning of a serious fetal condition.

In Costa Rica, where I live, only 24% of the population has received at least one vaccine dose because we have received very small amounts of vaccines. The Costa Rican president suggested that every person who can travel to the U.S. to get the jab, should do it. Vaccine tourism, then, seems to be another promising business opportunity for the powerful countries that have accumulated vaccines instead of redistributing them soon and fairly.

Many Latin American countries are being devastated by excessive loss of life from Covid-19, many sectors of society falling below the poverty line, and health systems being overwhelmed. As collateral damage, some countries in the region are witnessing an eruption of populism and autocratic trends and an increasing erosion of already weak and unstable democracies. Can bioethics be a useful tool for managing this crisis? Argentina provides a case study.

The C.D.C.'s latest policy guidance that people who have been fully vaccinated against the coronavirus virus no longer need to wear face masks indoors gets the science right, but policymaking wrong.

Citing the Yellow Card as precedent for Covid-19 travel passes that exempt those with proof of vaccination from testing and quarantine mandates when crossing certain borders is an erroneous policy assumption that could prolong the pandemic and imperil global health.

More than 100,000 people in this country are waiting for a life-saving transplant and on average 30 people die each day while waiting. The nonprofit organizations responsible for coordinating organ transplants between donors and recipient could be doing more to lower these numbers. A new government proposal designed to more closely regulate OPOs could, in some respects, actually make the situation worse.